Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02661048
Other study ID # CyberHeart Inc. -001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 27, 2015
Est. completion date July 6, 2023

Study information

Verified date September 2023
Source Varian, a Siemens Healthineers Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this clinical investigation is to evaluate: 1. the safety and efficacy of the CyberHeart System, CardioPlan™ Software and Laptop, in treating patients with refractory ventricular tachycardia (VT) using the CyberKnife® Radiosurgical System. 2. The CyberHeart System performance with respect to the ability to contour myocardial targets that are transferred to the Multi-plan® Treatment Planning Software of the CyberKnife® system for the production and delivery of a safe radiosurgical treatment plan. Cardiac radiosurgery is a minimally-non invasive, painless, procedure. Tissue ablation can be accomplished precisely.


Description:

This study is a prospective, multi-center (2), single arm, open label US-based feasibility study. The clinical hypothesis for the study is that the CyberHeart treatment approach will be safe and with further study will not be shown to be inferior to current treatment options, may lead to a survival benefit and improved quality of life. The ablation to be performed with the CyberHeart System will be targeting the anatomical site of the clinically presenting VT. The application site will be determined by morphological criteria on the 12 lead ECG along with anatomical data from MRI or CT scan imaging. Ablation will be performed at the designated location with the intention to produce substrate modification. The Study will enroll a maximum of 10 patients.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date July 6, 2023
Est. primary completion date July 6, 2023
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Presence of an implantable cardioverter-defibrillator (ICD) - Patients with ischemic or non-ischemic cardiomyopathy who have had recurrent symptomatic VT that induced ICD shock(s) following catheter ablation and/or antiarrhythmic drug (AAD) therapy. - 60 years of age or greater. - Left ventricular ejection fraction = 20%. - Failure of or ineligible for catheter ablation. Exclusion Criteria: - Unable or unwilling to provide informed consent - Patients with idiopathic VT - Women who are pregnant - Prior radiation therapy to the thorax - Active ischemia or other reversible causes of VT - Active non-cardiovascular illness or systemic infection - Presence of thrombus in the right atrium or right ventricle on pre-procedure echocardiogram - Cardiogenic shock - NYHA (New York Heart Association) Class IV Heart Failure. - Presence of incessant VT that is hemodynamically unstable. - Acute heart failure exacerbation. - Revascularization in the past 90 days. - Other disease process that is likely to limit survival to less than 12 months

Study Design


Intervention

Device:
CyberHeart System
The CyberHeart system uses proprietary software to assist the cardiologist to contour ablation targets. Standard radiosurgical techniques are then used to accomplish ablation

Locations

Country Name City State
United States Texas Cardiac Arrhythmia Research Foundation Austin Texas

Sponsors (1)

Lead Sponsor Collaborator
Varian, a Siemens Healthineers Company

Country where clinical trial is conducted

United States, 

References & Publications (1)

Loo BW Jr, Soltys SG, Wang L, Lo A, Fahimian BP, Iagaru A, Norton L, Shan X, Gardner E, Fogarty T, Maguire P, Al-Ahmad A, Zei P. Stereotactic ablative radiotherapy for the treatment of refractory cardiac ventricular arrhythmia. Circ Arrhythm Electrophysio — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Outcome 1 is the Number of participants with Treatment related Serious Adverse Events as assessed by CTCAE v. 4.0 Outcome 1 is measured by The number of Participants, and the percentage of participants with :
- Serious Adverse Events; (1) in the first 30 days, (2) in days 31 to 1 year post treatment, both treatment related, and non-treatment related, separately tabulated.
12 months (360 days) with Outcome assesment in first 30 days adn in days 31 to 1 year post treatment.
Secondary Number of participants with a change in SF-36 Medical Outcomes Health Survey, as compared to pre-treatment questionaire responses Participants will complete a SF-36 (Short Form-36) Medical Outcomes Survey before treatment and at each post treatment follow-up check. Absolute numeric numbers will be tabulated and percentage change will be calculated 12 months
Secondary Number of defibrillation shocks as compared to pretreatment occurrence Defibrillation shocks will be recorded pre-treatment and post treatment at each follow-up visit. 12 months
Secondary Ventricular arrhythmia episodes, as compared to pretreatment occurrence The number of ventricular tachycardia episodes that required either anti-tachycardia pacing, or that self-terminated, will be recorded pre- and post treatment. 12 months
Secondary Left ventricular function post treatment Left ventricular systolic and diastolic function will be assessed by echocardiography pre- and post treatment 12 months
See also
  Status Clinical Trial Phase
Terminated NCT01546207 - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia N/A
Completed NCT04075253 - Acute Effect of One Single Bout of High Intensity Exercise on the Tendency for Ventricular Arrhythmia N/A
Completed NCT04070300 - Physical Activity and Ventricular Arrhythmias N/A
Completed NCT00000531 - Antiarrhythmics Versus Implantable Defibrillators (AVID) Phase 3
Completed NCT00000480 - Multicenter Unsustained Tachycardia Trial (MUSTT) Phase 3
Completed NCT05086510 - Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping N/A
Completed NCT01940081 - The Leiden Nonischemic Cardiomyopathy Study
Recruiting NCT01222156 - Accuracy and Safety Study of the Magnetecs CGCI System for Intracardiac Mapping Phase 1/Phase 2
Terminated NCT00749671 - Bispectral Index Monitoring During Testing in the Electrophysiology Lab N/A
Recruiting NCT00385749 - Right Ventricular Defibrillation Lead Select Site Study N/A
Completed NCT00382928 - Automatic External Defibrillation Monitoring in Cardiac Arrest Phase 1
Completed NCT00279279 - PREPARE - Primary Prevention Parameters Evaluation N/A
Terminated NCT00776087 - European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco) N/A
Withdrawn NCT00510731 - The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of Ventricular Tachyarrhythmic Events N/A
Completed NCT01572246 - Effects of Monopolar Electrocautery Use During Surgery on Implanted Cardiac Defibrillators N/A
Completed NCT00170287 - SMS: Substrate Modification Study in Patients Getting an Implantable Cardioverter Defibrillator (ICD) Phase 4
Completed NCT00147277 - ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy Phase 4
Completed NCT00004559 - Fatty Acid Antiarrhythmia Trial (FAAT) Phase 3
Completed NCT00702117 - Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias Phase 4
Completed NCT00232297 - Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS Phase 2